ArticleFrontiers in cellular and infection microbiology2025
Busulfan inhibits
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: This study evaluated the antibacterial potential of busulfan against Results: Busulfan inhibited bacterial growth in a dose-dependent manner, with 84% inhibition observed at 108 μg/mL, whereas bactericidal activity was only observed at much higher concentrations (MBC >512 and <1,024 μg/mL). Busulfan significantly reduced biofilm formation by 55%, decreased live-cell viability by 67% as observed using confocal laser scanning microscopy (CLSM), decreased pyocyanin production by 57%, and impaired iron chelation by 25%. Moreover, moderate synergy with gentamicin was observed at higher concentrations of busulfan. However, treatment with 108 μg/mL busulfan showed no effect on PAO1 hemolysis or motility. Conclusion: Overall, busulfan demonstrates antimicrobial activity against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.